LifestyledAI, Dongguk University Startup Technology Institute & UMUST R&D Partner | To Advance Global AI Deep Tech and Healthcare Businesses

On August 28, 2024, Dongguk University Startup Technology Institute announced the signing of a joint MOU with LifestyledAI Co., Ltd. and UMUST R&D to advance global deep tech and healthcare initiatives through the application of LifestyledAI’s cutting-edge, proprietary AI technologies (patent-pending).

With this agreement, the parties plan to promote mutual cooperation with the goals of:

  • Collaborating on AI-based technology development and commercialization
  • Establishing strategies and providing technical support for exploring overseas markets
  • Joint research and development (international joint R&D, workshops, and seminars)
  • Exchanging research personnel
  • Creating an industry-academia cooperation ecosystem for mutual growth

LifestyledAI is an AI deep-tech startup that seeks to revolutionize customer lifestyles through its proprietary AI-based technologies, including AI Ultra-Real Fitting for highly realistic virtual fashion and beauty try-ons, and a precise, easy-to-use AI body measurement system. With a vision to become a global leader in the practical application of AI image technology, LifestyledAI is dedicated to enhancing user convenience in the fashion and beauty e-commerce industries through its innovative AI solutions. As a resident company in Dongguk University’s Startup Incubation Center, it receives extensive support in areas such as international market expansion, industry-academia collaboration, faculty consulting, technology transfer, and commercialization.

UMUST R&D Co., Ltd. is a renowned global healthcare startup focused on the development of global healthcare and AI technologies. Its core areas of expertise include the development of AI-based medical devices and healthcare solutions, leveraging cutting-edge technologies to drive innovation in the medical industry.

Jinwan Kim, CEO of LifestyledAI:

“This partnership will allow us to further refine our proprietary AI technologies and accelerate their global commercialization, helping to advance the AI deep-tech and healthcare industries on a global scale.”

Director Gwangho Yoo, Head of Dongguk University Startup Technology Institute, commented

“This agreement will facilitate a collaborative research and development framework in the AI and healthcare sectors by leveraging in-house technologies and matching human resources to strengthen industry-academia collaboration.”

Kangpa Lee, CEO of UMUST R&D, stated, “We are dedicated to advancing the AI image technologies developed by LifestyledAI and working together to implement these innovations in the development of cutting-edge AI medical devices, while also enhancing our global business capabilities.”

 

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.